Decreased Serum Oxytocin and Increased Homocysteine in First-Episode Schizophrenia Patients

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2019 Apr 27

PMID 31024366

Citations 16

Authors

Yong Liu

Huai Tao

Xiudeng Yang

Kai Huang

Xianghui Zhang

Cunyan Li

Affiliations

Soon will be listed here.

Abstract

Schizophrenia (SZ) is a debilitating and heterogeneous disease. We hypothesized that the oxytocin (OXT) system, inflammation and one-carbon metabolism would have a link with SZ. In this study, serum OXT, OXT receptor (OXTR), interleukin-6 (IL-6), high sensitivity CRP (hsCRP) and homocysteine (Hcy) levels were measured in 52 first-episode schizophrenia (FES) patients and 41 healthy controls (HC) from the Second Xiangya Hospital of Central South University. Meanwhile, the mRNA expressions of OXT and OXTR genes were determined by real-time quantitative PCR. Serum OXT and OXTR levels were significantly lower in FES patients (518.96 ± 22.22 and 174.60 ± 17.11 pg/ml) than the HC group (711.58 ± 40.57 and 252.15 ± 20.62 pg/ml). Serum IL-6 and hsCRP levels showed no difference between the two groups (1.82 ± 0.30 vs. 1.69 ± 0.36 pg/ml, 0.66 (0.22, 1.07) vs. 0.31 (0.13, 0.91) mg/L), but serum Hcy levels were significantly higher in FES patients (20.18 ± 1.83 vs. 15.24 ± 0.82 μmol/ml). The FES patients (0.27 ± 0.02 and 0.20 ± 0.02) have relatively higher mRNA expressions of OXT and OXTR genes than the HC group (0.16 ± 0.01 and 0.14 ± 0.01). In summary, our results suggested the possible function of the OXT system and Hcy in the pathogenesis of SZ.

Citing Articles

The Role of Oxytocin in Early-Life-Stress-Related Neuropsychiatric Disorders.

Jin Y, Song D, Yan Y, Quan Z, Qing H Int J Mol Sci. 2023; 24(13).

PMID: 37445607 PMC: 10342184. DOI: 10.3390/ijms241310430.

Effects of IL-6/IL-6R axis alterations in serum, plasma and cerebrospinal fluid with the schizophrenia: an updated review and meta-analysis of 58 studies.

Gonzalez-Castro T, Tovilla-Zarate C, Juarez-Rojop I, Hernandez-Diaz Y, Lopez-Narvaez M, Felicita Ortiz-Ojeda R Mol Cell Biochem. 2023; 479(3):525-537.

PMID: 37103677 DOI: 10.1007/s11010-023-04747-7.

Exploring a Possible Interplay between Schizophrenia, Oxytocin, and Estrogens: A Narrative Review.

Papadea D, Dalla C, Tata D Brain Sci. 2023; 13(3).

PMID: 36979271 PMC: 10046503. DOI: 10.3390/brainsci13030461.

Temporal profile of intranasal oxytocin in the human autonomic nervous system at rest: An electrocardiography and pupillometry study.

Cosme G, Arriaga P, Rosa P, Mehta M, Prata D J Psychopharmacol. 2023; 37(6):566-576.

PMID: 36891949 PMC: 10291383. DOI: 10.1177/02698811231158233.

Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.

Goh K, Chen C, Wu T, Chen C, Lu M Int J Mol Sci. 2022; 23(13).

PMID: 35806096 PMC: 9266532. DOI: 10.3390/ijms23137092.

References

Schneede J, Refsum H, Ueland P . Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost. 2000; 26(3):263-79. DOI: 10.1055/s-2000-8471. View

Gultepe M, Ozcan O, Avsar K, Cetin M, Ozdemir A, Gok M . Urine methylmalonic acid measurements for the assessment of cobalamin deficiency related to neuropsychiatric disorders. Clin Biochem. 2003; 36(4):275-82. DOI: 10.1016/s0009-9120(03)00033-x. View

Uvnas-Moberg K, Alster P, Svensson T . Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats. Psychopharmacology (Berl). 1992; 109(4):473-6. DOI: 10.1007/BF02247726. View

Muntjewerff J, Kahn R, Blom H, den Heijer M . Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2005; 11(2):143-9. DOI: 10.1038/sj.mp.4001746. View

Goldman M, Marlow-OConnor M, Torres I, Carter C . Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res. 2007; 98(1-3):247-55. PMC: 2277481. DOI: 10.1016/j.schres.2007.09.019. View

Petronijevic N, Radonjic N, Ivkovic M, Marinkovic D, Piperski V, Duricic B . Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(8):1921-6. DOI: 10.1016/j.pnpbp.2008.09.009. View

Benrick A, Schele E, Pinnock S, Wernstedt-Asterholm I, Dickson S, Karlsson-Lindahl L . Interleukin-6 gene knockout influences energy balance regulating peptides in the hypothalamic paraventricular and supraoptic nuclei. J Neuroendocrinol. 2009; 21(7):620-8. DOI: 10.1111/j.1365-2826.2009.01879.x. View

Loffler S, Loffler-Ensgraber M, Fehsel K, Klimke A . Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int Clin Psychopharmacol. 2010; 25(2):101-6. DOI: 10.1097/YIC.0b013e32833643fd. View

Souza R, De Luca V, Meltzer H, Lieberman J, Kennedy J . Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol. 2010; 13(6):793-8. DOI: 10.1017/S1461145710000167. View

10.

Miller B, Buckley P, Seabolt W, Mellor A, Kirkpatrick B . Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011; 70(7):663-71. PMC: 4071300. DOI: 10.1016/j.biopsych.2011.04.013. View

11.

Teltsh O, Kanyas-Sarner K, Rigbi A, Greenbaum L, Lerer B, Kohn Y . Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int J Neuropsychopharmacol. 2011; 15(3):309-19. DOI: 10.1017/S1461145711001374. View

12.

Zakharyan R, Petrek M, Arakelyan A, Mrazek F, Atshemyan S, Boyajyan A . Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens. 2012; 80(2):136-42. DOI: 10.1111/j.1399-0039.2012.01886.x. View

13.

Montag C, Brockmann E, Bayerl M, Rujescu D, Muller D, Gallinat J . Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study. World J Biol Psychiatry. 2012; 14(7):500-8. DOI: 10.3109/15622975.2012.677547. View

14.

Sasayama D, Hattori K, Teraishi T, Hori H, Ota M, Yoshida S . Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr Res. 2012; 139(1-3):201-6. DOI: 10.1016/j.schres.2012.06.016. View

15.

Fillman S, Cloonan N, Catts V, Miller L, Wong J, McCrossin T . Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2012; 18(2):206-14. DOI: 10.1038/mp.2012.110. View

16.

Na K, Jung H, Kim Y . The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 48:277-86. DOI: 10.1016/j.pnpbp.2012.10.022. View

17.

Lee M, Wehring H, McMahon R, Linthicum J, Cascella N, Liu F . Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res. 2013; 145(1-3):110-5. PMC: 4125132. DOI: 10.1016/j.schres.2013.01.001. View

18.

Sonne S, Bhalla V, Barman S, White R, Zhu S, Newman T . Hyperhomocysteinemia is detrimental to pregnancy in mice and is associated with preterm birth. Biochim Biophys Acta. 2013; 1832(8):1149-58. DOI: 10.1016/j.bbadis.2013.04.006. View

19.

Walss-Bass C, Fernandes J, Roberts D, Service H, Velligan D . Differential correlations between plasma oxytocin and social cognitive capacity and bias in schizophrenia. Schizophr Res. 2013; 147(2-3):387-92. DOI: 10.1016/j.schres.2013.04.003. View

20.

Nabi H, Bochud M, Glaus J, Lasserre A, Waeber G, Vollenweider P . Association of serum homocysteine with major depressive disorder: results from a large population-based study. Psychoneuroendocrinology. 2013; 38(10):2309-18. DOI: 10.1016/j.psyneuen.2013.04.018. View